--- title: "Caspian’s $50m round: Invus, Kura and the equity behind the financing | Altss Blog" description: "Invus joined Caspian’s $50m financing. Kura’s $4.3m investment, contributed IP and 49.2% equity position explain the difference between a round and a…" canonical: "https://altss.com/blog/caspian-kura-invus-financing-equity-contributions" --- [Altss Research](https://www.linkedin.com/company/altss) 4 min read Updated Oct 22, 2026 Share # Caspian’s $50m round: Invus, Kura and the equity behind the financing Invus joined Caspian’s $50m financing. Kura’s $4.3m investment, contributed IP and 49.2% equity position explain the difference between a round and a stake. [Back to blog](https://altss.com/blog) Share [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=) [X](https://x.com/intent/tweet?url=&text=Caspian%E2%80%99s%20%2450m%20round%3A%20Invus%2C%20Kura%20and%20the%20equity%20behind%20the%20financing) Copy link Caspian Therapeutics completed a $50 million Series A financing on September 8, 2026, with Invus among the named participants. Kura Oncology invested $4.3 million in the round and, immediately after completion, held approximately 49.2% of Caspian’s outstanding capital stock. The difference between those figures reflects more than a financing allocation: Kura also contributed intellectual property in exchange for common shares. For investors assessing the family-backed syndicate, the transaction provides a disclosed corporate investment alongside an undisclosed Invus ticket. It also shows why a cash investment and an equity position need separate explanations. Caspian received financing to develop a business built around assets originating at Kura; Kura retained exposure through both common and preferred stock. ## A financing share is different from an ownership share Kura’s [September 9 Form 8-K](https://www.sec.gov/Archives/edgar/data/1422143/000119312526385881/d496500d8k.htm) describes the previous day’s sale and issuance of $50 million of Caspian Series A preferred stock. Kura’s $4.3 million investment represents 8.6% of that financing. The remaining $45.7 million is the combined amount invested by the other participants, without an allocation among them. The 49.2% figure has a different denominator. It combines Kura’s common stock and Series A preferred stock as a percentage of Caspian’s outstanding capital stock immediately after the financing. It therefore cannot be read as the percentage of the round subscribed by Kura. The [launch announcement](https://caspiantherapeutics.com/press-release/kura-oncology-launches-caspian-therapeutics-with-50-million-financing-to-advance-menin-inhibition-as-a-potential-disease-modifying-approach-for-diabetes/) separately describes Kura’s position as approximately half on a fully diluted basis; the filing’s more precise percentage retains its own stated basis. Under a separate contribution agreement, Kura transferred specified rights to next-generation menin inhibitors for diabetes and cardiometabolic diseases, including KO-7246, together with related intellectual property and other assets. It received Caspian common shares and a reimbursement payment of up to $1.5 million for maintaining those assets before closing. That capped reimbursement is a payment to Kura, rather than an additional contribution by Kura to the $50 million financing. The filing does not assign a monetary value to the common shares issued for those assets. Dividing Kura’s investment by its combined ownership percentage would consequently mix a financing subscription with equity issued for a separate contribution. The disclosed figures do not provide a clean post-money valuation or a price for the intellectual property. ## Separate financing, continuing operating ties The transaction also allocates development responsibility. Caspian is responsible for developing, securing regulatory approvals for and commercializing products containing the contributed assets in diabetes and other cardiometabolic diseases. The arrangement gives that development program a separately financed company while Kura’s announcement says it remains focused on oncology. The companies retain contractual links. Their contribution agreement includes reciprocal licenses with specified research and field-of-use scopes. Separately, Kura agreed to provide research and development, general administrative and other agreed services to Caspian for fees. The services agreement has an initial one-year term and successive annual renewals unless notice is given; Caspian also has a termination-for-convenience provision subject to notice. Those service fees are a continuing operating relationship distinct from Kura’s equity exposure. Royalty-free licenses described in the contribution agreement do not make the separate services arrangement free. The filing does not quantify the service fees, so their effect on Caspian’s financing runway cannot be calculated from these disclosures. ## Where the family-backed capital enters The issuer names BVF Partners as the financing’s lead investor and lists Invus alongside T1D Fund, Montanova, Eli Lilly and Company, Kura, members of Kura’s leadership team and biotech entrepreneurs. [Invus’s own profile](https://invus.com/who-we-are/) says its source of capital since its founding has been Artal, a European family group with a continuous capital structure. That establishes the family-capital connection without assigning Artal a separate direct Caspian shareholding. Invus’s individual investment amount and ownership percentage are not disclosed in the inspected announcement or filing. Neither the $50 million round nor the $45.7 million collective remainder can be attributed to it. This extends the distinction between [company financing and family-investor participation](https://altss.com/blog/family-backed-direct-investments-october-2026-company-rounds-platform): here, even a disclosed participant’s investment amount does not explain its entire equity position when contributed assets also earn shares. Share this article Share ## Related articles [Image: Top 6 Private-Company Deal-Sourcing Databases Used by PE & VC Firms (2026)](https://altss.com/blog/top-6-private-company-deal-sourcing-databases-used-by-pe-and-vc-firms-2025) Private Markets 18 min read ### [Top 6 Private-Company Deal-Sourcing Databases Used by PE & VC Firms (2026)](https://altss.com/blog/top-6-private-company-deal-sourcing-databases-used-by-pe-and-vc-firms-2025) Updated for 2026: the six platforms buy-side teams actually use—PitchBook, S&P Capital IQ Pro, SourceScrub, Grata, CB Insights, and Altss—with ownership ch [Altss Research](https://www.linkedin.com/company/altss) Oct 6, 2025 [Image: A removable report face for Citadel and a separate reveal shield for HBK illustrate restatement versus later disclosure of historical holdings.](https://altss.com/blog/13f-amendments-restatement-new-holdings-citadel-hbk) Private Markets 4 min read ### [13F amendments: replacing a report or adding previously omitted holdings](https://altss.com/blog/13f-amendments-restatement-new-holdings-citadel-hbk) 13F restatements and additions need different dataset operations. Exact Citadel and HBK filings show reporting-period and entry-count boundaries. [Altss Research](https://www.linkedin.com/company/altss) Oct 15, 2026 [Image: A three-date comparison instrument separates June30 holdings, August14 filing and October15 observation,107days after the holdings date.](https://altss.com/blog/13f-october-2026-june-holdings-q3-reporting-deadline) Private Markets 6 min read ### [13F dates in October 2026: June holdings and the Q3 deadline](https://altss.com/blog/13f-october-2026-june-holdings-q3-reporting-deadline) Original Q2 filings and current SEC guidance explain holdings dates, filing dates, the Q3 deadline and what an October 13F observation can establish. [Altss Research](https://www.linkedin.com/company/altss) Oct 15, 2026 ## Canonical URL https://altss.com/blog/caspian-kura-invus-financing-equity-contributions